Chronic Pain and Sleep Disturbances: A Dangerous Coexistence Renato Vellucci * Department of Pain and Palliatve Care, University of Florence, University Hospital of Careggi, Florence, Italy * Corresponding author: Renato Vellucci, Department of Pain and Palliatve Care, University of Florence, University Hospital of Careggi, Florence, Italy, Tel: +39 3383 432 614; E-mail: renato.vellucci@gmail.com Received date: June 25, 2021; Accepted date: July 09, 2021; Published date: July 16, 2021 Citaton: Vellucci R (2021) Chronic Pain and Sleep Disturbances: A Dangerous Coexistence. Int J Anesth Pain Med Vol.7 No.4:50. Abstract Chronic Pain (CP) new defniton has brought benefts to address the complexity of this syndrome. Quality of Life (QoL) and Functonal Recovery (FR) represent fundamental issues of clinical outcomes, which go beyond mere pain relief. Such a defniton recognizes the bidirectonal associaton between CP and SD. Patents who sufer from CP always have Sleep Disturbances (SD). These patents may feel agitated during the night and tred in the morning, leading to a signifcant decrease in personal productvity. The two-way relatonship between poor sleep and pain operates to maintain and amplify sleep inadequacy and growth and intensifcaton of pain. There is a great need to increase awareness on the contributon of sleep quality to the severity of functonal impairment in CP patents. CP disorders are not a simple exacerbaton of acute pain. The negatve efect of pain and sleep problems on quality of life outlines the necessity for investgatng how the two conditons are associated and how to structure treatments and preventon strategies. Keywords: Chronic pain; Functonal recovery; Cognitve functon; Dementa; Analgesics Descripton The new defniton of CP as a single disease entty has brought benefts in terms of defniton of severity [1]. Now this issue is best described through a multdimensional framework, acknowledging both the multdimensional nature of pain and the evolving noton of pain as a biopsychosocial issue. Furthermore, it may address fundamental topics like QoL and FR, adding further emphasis to clinical outcomes which go beyond mere pain relief. During the past decades, QoL and FR have progressively emerged as two important goals of analgesic therapy. The biopsychosocial evoluton of CP model induces us to consider functonality as an ensemble of factors, such as the ability to return to work, maintain cognitve functon, and complete actvites of daily living as well as the absence of mood and SD. Such a defniton recognizes the bidirectonal associaton between CP and SD [2], and redefnes sleep quality as a new target of analgesic therapy. Poor sleep could lead to a signifcant decrease in personal productvity, playing a role in terms of fnancial and non-fnancial costs, becoming an important social and economic burden [3]. Sleep quality plays a key role in cognitve and emotonal functoning, representng a risk factor for obesity, cardiovascular disease, diabetes, dementa, immune suppression, and mortality. Moreover, pain disorganizes sleep architecture, and disturbed and unrefreshing sleep increases spontaneous pain and lowers pain thresholds [4]. This two-way relatonship between poor sleep and pain operates to maintain and amplify sleep inadequacy and growth and intensifcaton of pain via a downward spiral, which perpetuates and amplifes itself over tme. Epidemiology of CP demonstrates the role of sleep quality in the development of CP and vice versa. Notwithstanding this, at least theoretcal, strong two-way relatonship between CP an SD, litle knowledge is available about the neurochemical determinants of this interplay and about the therapeutcal strategies to break this vicious circle [5]. There is a great need to increase awareness on the contributon of sleep quality to the severity of functonal impairment in CP patents. Furthermore, it is crucial to acquire knowledge of how pain intensity reducton may improve sleep quality as a result of analgesic drugs. The close relatonship between sleep and chronic pain CP disorders are not a simple exacerbaton of acute pain but require a switch of pain-processing mechanisms to a pathological state that may last indefnitely [6]. Opioid receptors are situated in several nuclei that actvely control both sleep and pain. Many decades ago, it was hypothesized the potental involvement of the opioid system in sleep deprivaton in inducing pain hypersensitvity [7]. Recently, the damage of inhibitory neuromodulaton of pain has been demonstrated in many clinical pain disorders, with prominent sleep disturbance components [8-10]. Moreover, sleep deprivaton imbalances endogenous opioid systems and decreases the analgesic efcacy of μ-opioid receptor agonists. Key neuroimaging fndings in insomnia patents revealed overactvity in cortcolimbic areas, controlled by monoaminergic (serotonergic and noradrenergic) pathways [11]. The cortcolimbic brain areas primarily include the medial prefrontal cortex, amygdala, nucleus accumbens and hippocampus. These areas are also involved in the pathophysiology of certain CP conditons that appear to be aggravated in patents with sleeplessness. Clinical neuroimaging studies demonstrate a fundamental involvement of the cortcolimbic system in the development, amplifcaton and prognosis of chronic pain. Short Communication iMedPub Journals www.imedpub.com International Journal of Anesthesiology and Pain Medicine ISSN 2471-982X Vol.7 No.4:50 2021 © Copyright iMedPub | This article is available from: https://anaesthesia painmedicine.imedpub.com/ 1